Riley Kandel

LY4170156 was well tolerated and generated promising efficacy data in patients with recurrent, platinum- resistant high-grade serous ovarian cancer.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data from real-world analysis of treatment patterns in high-risk mantle cell lymphoma and their implications.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data with an acalabrutinib-based regimen in high-risk mantle cell lymphoma from the WINDOW-3 trial.

Andrea Franson, MD, MS, discusses safety data on tovorafenib in relapsed or refractory pediatric low-grade glioma from the FIREFLY-1 trial.

Obe-cel was associated with lower rates of CRS and ICANS vs brexu-cel in relapsed or refractory acute lymphoblastic leukemia.

Zev A. Wainberg, MD, discusses different palliative chemotherapy regimens, their use cases, and other recent developments in pancreatic cancer.

Neoadjuvant SAbR before nephrectomy improved 12-month RFS vs surgery alone in RCC with IVC tumor thrombus, with manageable safety.

Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.

Phase 1 data showed that LP-184 displayed an acceptable safety profile and was well-tolerated in heavily-pretreated patients with advanced solid tumors.

FOG-001 demonstrated a manageable safety profile in addition to antitumor activity that was clinically meaningful in patients with desmoid tumors.

Venetoclax in combination with enzalutamide displayed a favorable safety profile as a treatment regimen for mCRPC.

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

Anito-cel showed deepening responses in patients with relapsed or refractory myeloma enrolled in the phase 2 iMMagine-1 study.

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.

Larry Anderson, MD, PhD, FACP, discusses data from AURIGA showing that daratumumab plus lenalidomide is a favorable maintenance regimen in multiple myeloma.

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

BTK and PI3K inhibition produced responses but unexpected PK data in relapsed/refractory PCNSL.

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

OBI-902 received orphan drug designation from the FDA for the treatment of patients with cholangiocarcinoma.

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

ZEN-3694 obtained orphan drug designation from the FDA for the treatment of NUT carcinoma.

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.